Mark Baldry's most recent trade in X4 Pharmaceuticals Inc was a trade of 1,032 Common Stock done at an average price of $2.5 . Disclosure was reported to the exchange on May 16, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| X4 Pharmaceuticals Inc | Mark Baldry | Chief Commercial Officer | Purchase of securities on an exchange or from another person at price $ 2.48 per share. | 16 May 2025 | 1,032 | 25,337 (0%) | 0% | 2.5 | 2,561 | Common Stock |
| X4 Pharmaceuticals Inc | Mark Baldry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 2.48 per share. | 16 May 2025 | 1,032 | 25,337 (0%) | 0% | 2.5 | 2,561 | Common Stock |
| X4 Pharmaceuticals Inc | Mark Baldry | Chief Commercial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Jan 2025 | 74,773 | 123,282 (0%) | 0% | 0 | Common Stock | |
| X4 Pharmaceuticals Inc | Mark Baldry | Chief Commercial Officer | Sale of securities on an exchange or to another person at price $ 0.45 per share. | 23 Jan 2025 | 29,159 | 94,123 (0%) | 0% | 0.5 | 13,241 | Common Stock |